



May 27, 2025

**Launch of Radicava® for the Treatment of ALS in Australia**

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; President, Representative Director: Akihiro Tsujimura, hereinafter “MTPC”) announced today that Radicava® (generic name: edaravone, Japanese product name: RADICUT® inj.30mg) for an intravenous treatment for amyotrophic lateral sclerosis (ALS) has been launched in Australia on May 1 by a local licensee, Teva Pharma Australia Pty Ltd.

Radicava® is a free radical scavenger developed by MTPC. It is assumed to have the effect of scavenging free radicals that increase in levels in the ALS pathology, protecting motor neurons from oxidative stress, and slowing the progression of muscle weakness and muscle atrophy.

To maximize availability of Radicava® for patients, MTPC has been expanding the countries where the product could be available and developing oral formulation as a new route of administration. Edaravone was approved for the treatment of ALS in Japan, June 2015, followed by South Korea, U.S., Canada, Switzerland, Indonesia, Thailand, Malaysia, and Brazil is marketed.

MTPC will strive to provide Radicava® to patients fighting against ALS all over the world.

<p><i>Contact:</i> Mitsubishi Tanabe Pharma Corporation CEO Office PR Group +81-6-6205-5119</p>
---

■ Teva Pharma Australia Pty Ltd.

Teva Pharma Australia Pty Ltd. is a subsidiary of Teva Pharmaceutical Industries. Teva is a global pharmaceuticals leader focused on delivering high-quality medicines and innovative healthcare solutions to improve patient lives around the world.